Suggest you chill out and have a cuppa! I have complimented the CEO and his participation in various prior issues and also on his scientific knowledge on previous posts. I am simply making a realistic comment on what it would cost to do the extended and necessary further AZ trial post interim analysis.
I can have my own opinion on what I believe is their required cash expenditure over the next 12mths. Based on their past recruitment delays I would not be surprised to also see delays in fulfilling the patient requirements in the AZ interim analysis as well!
Ann: Positive Xanamem biomarker trial published in Jnl Alz Dis, page-70
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACW (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.4¢ |
Change
-0.001(4.00%) |
Mkt cap ! $70.68M | |||
| Open | High | Low | Value | Volume |
| 2.5¢ | 2.5¢ | 2.4¢ | $133.5K | 5.461M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 4693575 | 2.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.5¢ | 8756804 | 6 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| ACW (ASX) Chart |